How many boxes of adagrasib should be consumed in a month? Medication planning and economic burden analysis

The recommended dosage of adagrasib for the treatment of non-small cell lung cancer (NSCLC) and colorectal cancer (mCRC) is 600 mg orally twice a day until disease progression or unacceptable toxicity occurs. Taking the specification of 200 mg per tablet as an example, patients need to take 3 tablets per day. According to this medication plan, the patient will need to take 180 pills a month. After conversion, the monthly drug requirement is a box of 200mg*180 pills.

However, since adagrasib is not yet available in the country, patients can only purchase the drug through overseas channels. In the U.S. market, the price of the original drug of adagrasib is relatively high. A box of 200mg*180 tablets usually sells for thousands of dollars. The specific price may vary according to different regions and exchange rates. For some patients, especially those on long-term medication, this cost will become a considerable financial burden.

Although the price of the original drug is higher, generic versions of adagrasib have also appeared on the market, especially in Southeast Asia. The generic version of adagrasibu produced in Laos is 200mg*90 tablets, and the price is relatively cheap, usually around 3,000 yuan. This allows some patients with limited financial conditions to choose generic drugs to reduce the burden of treatment. The therapeutic effects of generic drugs are similar to those of the original drugs, and they can provide patients with feasible treatment options.

However, even if they choose to purchase lower-priced generic drugs, patients still face certain financial pressures, especially those on long-term treatment. In the absence of medical insurance support, patients need to carefully evaluate their financial situation and weigh the relationship between treatment effects and costs. As adagrasib may enter the Chinese market and be reimbursed by medical insurance in the future, patients' financial burden is expected to be alleviated and treatment accessibility will be further improved.

Reference materials：https://www.krazati.com/